The Goldman Sachs Group Downgrades REGENXBIO (NASDAQ:RGNX) to Neutral
REGENXBIO (NASDAQ:RGNX – Get Free Report) was downgraded by analysts at The Goldman Sachs Group from a “buy” rating to a “neutral” rating in a report issued on Tuesday, MarketBeat reports. They presently have a $14.00 price objective on the biotechnology company’s stock, down from their prior price objective of $38.00. The Goldman Sachs Group’s […]
REGENXBIO (NASDAQ:RGNX – Get Free Report) was downgraded by analysts at The Goldman Sachs Group from a “buy” rating to a “neutral” rating in a report issued on Tuesday, MarketBeat reports. They presently have a $14.00 price objective on the biotechnology company’s stock, down from their prior price objective of $38.00. The Goldman Sachs Group’s […]
